Drug Profile
VECAM - Vecta
Alternative Names: Esomeprazole/succinate acid; Omeprazole/succinic acid; PPI/VB101; Proton pump inhibitor/succinic acid; VB101; VB101/PPI; VCT-111; VECAM; Vecam 20/300; Vecam 40/300; VECAM-110; VECAM-111Latest Information Update: 28 Aug 2015
Price :
$50
*
At a glance
- Originator Vecta
- Class Antiulcers; Small molecules; Succinic acids
- Mechanism of Action Proton pump inhibitors; Proton pump stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Gastro-oesophageal reflux
Most Recent Events
- 28 Aug 2015 No recent reports on development identified - Phase-II for Gastro-oesophageal reflux in USA (PO)
- 30 Jun 2011 Vecta completes a phase IIb trial in Gastro-oesophageal reflux in USA (NCT01059383)
- 17 Sep 2010 VB 101 is available for licensing as of 30 Jun 2009. http://www.vecta.co.il